Last reviewed · How we verify
Canagliflozin and Gemcitabine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Canagliflozin and Gemcitabine (Canagliflozin and Gemcitabine) — Zhang Xiaofeng,MD.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Canagliflozin and Gemcitabine TARGET | Canagliflozin and Gemcitabine | Zhang Xiaofeng,MD | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Canagliflozin and Gemcitabine CI watch — RSS
- Canagliflozin and Gemcitabine CI watch — Atom
- Canagliflozin and Gemcitabine CI watch — JSON
- Canagliflozin and Gemcitabine alone — RSS
Cite this brief
Drug Landscape (2026). Canagliflozin and Gemcitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/canagliflozin-and-gemcitabine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab